Beam Therapeutics (BEAM) Other Operating Expenses (2019 - 2021)

Beam Therapeutics (BEAM) has reported Other Operating Expenses for 7 consecutive years, with $384.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Operating Expenses rose 411.04% year-over-year to $384.6 million; the TTM figure through Mar 2026 stood at $260.0 million (up 209.39% YoY), while the FY2024 annual figure was -$462.2 million, up 8.91% from the prior year.
• Other Operating Expenses rose to $384.6 million in Q4 2025 per BEAM's latest filing, from -$124.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $384.6 million in Q4 2025 and bottomed at -$507.4 million in Q4 2023.
• Historically, Other Operating Expenses has averaged -$119.7 million across 5 years, with a median of -$118.9 million in 2024.
• Annual changes were most pronounced in 2023 — Other Operating Expenses tumbled 38.83% — and 2025, when it jumped 411.04%.
• Beam Therapeutics' Other Operating Expenses stood at -$1.2 million in 2021, then tumbled by 30688.63% to -$365.5 million in 2022, then tumbled by 38.83% to -$507.4 million in 2023, then surged by 75.63% to -$123.6 million in 2024, then surged by 411.04% to $384.6 million in 2025.
• Business Quant data shows BEAM's Other Operating Expenses at $384.6 million in Q4 2025, -$124.5 million in Q3 2025, and -$123.6 million in Q4 2024.